Clinical Trials Logo

Clinical Trial Summary

The study aims to answer this question: whether adequate immunity can be achieved in a short time, that is, by a rapid immunisation process, using at least one of 3 new TBE immunisation schedules? The investigators will test the immunogenicity (the degree of immunity achieved) of each of the immunisation schedules at various times after the injections. If the results of this clinical study are positive, it may then be possible to develop the most successful immunisation schedule so that it can be used routinely. This means that the results of the clinical study have an enormous practical value in preventing TBE in people travelling or moving into areas with a high TBE risk.


Clinical Trial Description

The data from at least 99 individuals will be needed if the study is to draw reliable conclusions. One-third of these individuals will receive 3 injections in all: 2 on the first day and the third injection 4 days later (immunisation schedule 1). Another one-third will receive 2 injections in all: one on the first day and one injection 4 days later (immunisation schedule 2). The remaining one-third will also receive 2 injections, both of these on the first day (immunisation schedule 3). Participants will be assigned completely randomly (by chance) to one of these three groups. So each participant stands a 33% chance (a 1:2 chance) of receiving any one particular immunisation schedule. If you agree to take part, the process will be as follows:

Brief Overview of the Course of the Clinical Study:

Vaccination scheme 1

Vaccination scheme 2

Vaccination scheme 3

Vaccinations:

I = Vaccination with FSME-IMMUN 0,5ml

- Scheme 1: 2 vaccinations at U1 (day 0), one injection into the left and the right upper arm each, 1 vaccination at U2 (day 4), injection into the left upper arm

- Scheme 2: one vaccination at U1 (day 0) and at U2 (day 4), injections into the left upper arm each

- Scheme 3: 2 vaccinations at U1 (day 0), one injection into the left and the right upper arm each ;


Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention


Related Conditions & MeSH terms


NCT number NCT00890422
Study type Interventional
Source Elisabethinen Hospital
Contact
Status Active, not recruiting
Phase Phase 2
Start date March 2007
Completion date July 2010

See also
  Status Clinical Trial Phase
Recruiting NCT03956446 - Tick-borne Encephalitis and Borrelial Antibodies in Serum N/A
Completed NCT01562444 - Study to Evaluate Long Term Immunogenicity up to 10 Years After the First Booster Immunization With Tick Borne Encephalitis Vaccine in Adults Who Received 1 of 3 Different Primary Vaccination Schedules Phase 4
Completed NCT01991067 - Humoral and Cellular Immunity for TBE Vaccination in Allogeneic HSCT Recipients Phase 2
Completed NCT03958058 - Tick-borne Encephalitis and Possible Borrelial Serology
Active, not recruiting NCT04017052 - Application of a TBE-Vaccine in Obese Persons Phase 4